newsfilter
← Latest News
PR Newswire·

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

First presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders, respectively A higher proportion of patients treat